The estimated Net Worth of Terry J Rosen is at least $6.84 millió dollars as of 16 December 2022. Terry Rosen owns over 13,043 units of Arcus Biosciences Inc stock worth over $4,109,676 and over the last 7 years he sold RCUS stock worth over $1,012,272. In addition, he makes $1,716,900 as Chairman of the Board, Chief Executive Officer és Co-Founder at Arcus Biosciences Inc.
Sign up
Terry Rosen RCUS stock SEC Form 4 insiders trading
Terry has made over 13 trades of the Arcus Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 13,043 units of RCUS stock worth $401,072 on 16 December 2022.
The largest trade he's ever made was buying 66,666 units of Arcus Biosciences Inc stock on 19 March 2018 worth over $999,990. On average, Terry trades about 9,185 units every 56 days since 2018. As of 16 December 2022 he still owns at least 242,173 units of Arcus Biosciences Inc stock.
You can see the complete history of Terry Rosen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Terry Rosen biography
Dr. Terry J. Rosen Ph.D. serves as Chairman of the Board, Chief Executive Officer, Co-Founder of the Company. He also served as the Chief Executive Officer of PACT Pharma, Inc., a biopharmaceutical company, from November 2016 to December 2017. Immediately prior to the founding of our company, Dr. Rosen served briefly in April 2015 as the Chief Executive Officer of FLX Bio, Inc., a biopharmaceutical company that was spun-off by Flexus Biosciences, Inc., a biopharmaceutical company. Previously, Dr. Rosen co-founded (with Dr. Jaen) and served as the Chief Executive Officer of Flexus Biosciences, Inc. from October 2013 to April 2015, when it was acquired by Bristol-Myers Squibb. Prior to that, Dr. Rosen was at Amgen, Inc., a biopharmaceutical company, from 2004 to January 2013 where he most recently served as Vice President of Therapeutic Discovery from 2011 to January 2013. He also worked at Tularik Inc., a biopharmaceutical company, from 1993 to 2004 when it was acquired by Amgen, Pfizer Central Research, a biopharmaceutical company, from 1987 to 1993, and Abbott Laboratories, a health care company, from 1985 to 1987. Dr. Rosen serves on the board of trustees of the Salk Institute, the California Life Sciences Association and the Berkeley Foundation. He also serves on the boards of Ideaya Biosciences, Inc., PACT Pharma, Epiodyne, Inc. and Simcha Therapeutics Holding Company, LLC. Dr. Rosen also serves on the Scientific Advisory Board of Sirenas, LLC. Dr. Rosen holds a B.S. in Chemistry from the University of Michigan and a Ph.D. in Chemistry from the University of California, Berkeley. Rosen should serve as a director based on his position as one of our founders and as our Chief Executive Officer, his extensive experience in general management and business development and his experience in the field of biosciences.
What is the salary of Terry Rosen?
As the Chairman of the Board, Chief Executive Officer és Co-Founder of Arcus Biosciences Inc, the total compensation of Terry Rosen at Arcus Biosciences Inc is $1,716,900. There are 2 executives at Arcus Biosciences Inc getting paid more, with William Grossman having the highest compensation of $3,400,310.
How old is Terry Rosen?
Terry Rosen is 61, he's been the Chairman of the Board, Chief Executive Officer és Co-Founder of Arcus Biosciences Inc since 2017. There are 3 older and 12 younger executives at Arcus Biosciences Inc. The oldest executive at Arcus Biosciences Inc is Yasunori Kaneko, 66, who is the Lead Independent Director.
What's Terry Rosen's mailing address?
Terry's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Insiders trading at Arcus Biosciences Inc
Over the last 7 years, insiders at Arcus Biosciences Inc have traded over $12,714,957 worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth $566,530,309 . The most active insiders traders include Patrick Machado, Sciences, Inc. Gilead és Harbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of $5,400,635. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth $20,314.
What does Arcus Biosciences Inc do?
arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
What does Arcus Biosciences Inc's logo look like?
Complete history of Terry Rosen stock trades at Arcus Biosciences Inc és IDEAYA Biosciences
Arcus Biosciences Inc executives and stock owners
Arcus Biosciences Inc executives and other stock owners filed with the SEC include:
-
William Grossman,
Chief Medical Officer -
Juan Jaen,
President, Co-Founder, Director -
Terry Rosen,
Chairman of the Board, Chief Executive Officer, Co-Founder -
Jennifer Jarrett M.B.A.,
COO & Director -
Jennifer Jarrett,
Chief Operating Officer, Director -
Patrick Machado,
Director -
Antoni Ribas,
Director -
Yasunori Kaneko,
Lead Independent Director -
Kathryn Falberg,
Independent Director -
Merdad Parsey,
Director -
David Lacey,
Director -
Eric Hoefer,
Chief Commercial Officer & Head of Business Development -
Jason Barker,
Vice President - Finance -
Robert Goeltz,
Chief Financial Officer, Principal Financial and Accounting Officer -
Yvonne Gehring,
VP of HR & Operations -
Holli Kolkey,
VP of Corp. Communications -
Carolyn C. Tang J.D.,
Gen. Counsel & Corp. Sec. -
Katherine Bock,
VP of Investor Relations & Corp. Strategy -
Dr. Jonathan Yingling Ph.D.,
Chief Scientific Officer -
Dr. Stephen Young Ph.D.,
Sr. VP of Technology & Quantitative Biology -
Robert C. Goeltz II,
Principal Financial & Accounting Officer and CFO -
Dr. Juan Carlos Jaen Ph.D.,
Co-Founder, Pres & Director -
David W Beier,
Director -
Carolyn C. Tang,
General Counsel -
Harbor Master Investors (Ca...,
10% owner -
2016 Gp, L.L.C.Gv 2016 Gp, ...,
-
2017 Gp, L.L.C.Gv 2017 Gp, ...,
-
Group Ii, Lp Column Group I...,
-
Kristen Hege,
Director -
Steven Chan,
See Remarks -
Rekha Hemrajani,
See Remarks -
Sciences, Inc. Gilead,
10% owner -
Nicole Lambert,
Director -
Dimitry Sa Nuyten,
Chief Medical Officer -
Alexander Azoy,
Chief Accounting Officer